1. Roche Sequencing
  2. NGS Oncology Assays
  3. AVENIO Tumor Tissue Analysis Kits
  4. AVENIO Tumor Tissue Targeted Kit

AVENIO Tumor Tissue Targeted Kit

Overview

The AVENIO Tumor Tissue Targeted Kit is a next-generation sequencing (NGS) assay for comprehensive genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue samples.  It contains 17 guideline-aligned biomarkers, including those in the U.S. National Comprehensive Cancer Network (NCCN).1   

Features and Benefits of AVENIO Tumor Tissue Targeted Kits

  • Panel content exactly-matched to gene panel in the AVENIO ctDNA Targeted Kit (same genes, gene regions and hybrid-capture workflow) to facilitate analytical concordance between tissue and plasma
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow with exceptional sensitivity and specificity1
  • 99% success rate for FFPE tissue samples that pass input QC testing using the AVENIO QC kit included with the assay
  • Flexibility to switch between tissue and plasma to support a variety of research applications
  • A streamlined, end-to-end workflow from extraction to analysis and reporting in 5 days
  • Includes reagents for DNA extraction, library preparation and target enrichment, as well as bioinformatics and software required to analyze sequencing data and generate reports

Exceptional Performance

View the detailed Gene List for the AVENIO Expanded Panel

References

  1. Data on file.
  2. National Comprehensive Cancer Network. October 15, 2016.

Research Use Only. Not for use in diagnostic procedures.
AVENIO is a trademark of Roche. All other product names and trademarks are the property of their respective owners.